Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Silence Therapeutics PLC
Start Date
March 26, 2024
End Date
March 14, 2029
Administered By
Duke Cancer Institute
Awarded By
Silence Therapeutics PLC
Start Date
March 26, 2024
End Date
March 14, 2029